Patents by Inventor Stefan Robbert Braam

Stefan Robbert Braam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11773375
    Abstract: The present invention is in the field of pluripotent stem cells, more particularly cardiomyocytes derived from pluripotent stem cells. The present invention provides a novel method for differentiating human pluripotent stem cells into a population of cardiomyocytes having an atrial phenotype, and use of said atrial cardiomyocytes for screening of drugs, AF disease model, and others. The method of the invention is particularly useful to generate cardiomyocytes having a more developed or mature atrialphenotype and/or to generate higher yield of cardiomyocytes having an atrialphenotype.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 3, 2023
    Assignee: Ncardia B.V.
    Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela, Karin Langenberg
  • Publication number: 20230295570
    Abstract: The present invention is in the field of pluripotent stem cells. In particular the invention relates to a method for (closed system) induction of differentiation of pluripotent stem cells towards a pre-selected cell type, such as, for example, cardiomyocytes or endothelial cells. The method as disclosed herein is particularly useful to upscale the production of cells derived from pluripotent stem cells, in particular (human) cardiomyocytes and/or endothelial cells derived from pluripotent stem cells.
    Type: Application
    Filed: July 23, 2021
    Publication date: September 21, 2023
    Inventor: Stefan Robbert BRAAM
  • Publication number: 20220025333
    Abstract: The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 27, 2022
    Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela
  • Patent number: 11136551
    Abstract: The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 5, 2021
    Assignee: NCARDIA B.V.
    Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela
  • Publication number: 20210147805
    Abstract: The current invention relates to finding that stem cell derived, for example induced pluripotent stem cell derived, cardiomyocytes with both a matured electrophysiological phenotype and optical excitability for high-fidelity beating frequency modulation may be obtained. With the method of the invention stem cell derived cardiomyocytes may obtained that show a mature phenotype in comparison to the same stem cell derived cardiomyocytes not be subjected to the method of the invention disclosed herein, the latter displaying an immature phenotype.
    Type: Application
    Filed: September 21, 2018
    Publication date: May 20, 2021
    Inventors: Benjamin WOLTERS, Ralf KETTENHOFEN, Heribert BOHLEN, Stefan Robbert BRAAM
  • Publication number: 20200370018
    Abstract: The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC).
    Type: Application
    Filed: June 11, 2020
    Publication date: November 26, 2020
    Inventor: Stefan Robbert Braam
  • Patent number: 10844354
    Abstract: This disclosure generally concerns the fields of cell biology and molecular biology. In particular the invention concerns the field of stem cell biology and maturation of stem cell-derived cardiomyocytes. Disclosed is a method for improving the maturity of stem-cell derived cardiomyocytes, in particular of the ventricular type, as can be witnessed by, for example, an improved upstroke velocity of the stem-cell derived cardiomyocytes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 24, 2020
    Assignee: NCARDIA B.V.
    Inventors: Stefan Robbert Braam, Leon Tertoolen, Christine Mummery
  • Publication number: 20200216812
    Abstract: The present invention is in the field of pluripotent stem cells, more particularly cardiomyocytes derived from pluripotent stem cells. The present invention provides a novel method for differentiating human pluripotent stem cells into a population of cardiomyocytes having an atrial phenotype, and use of said atrial cardiomyocytes for screening of drugs, AF disease model, and others. The method of the invention is particularly useful to generate cardiomyocytes having a more developed or mature atrialphenotype and/or to generate higher yield of cardiomyocytes having an atrialphenotype.
    Type: Application
    Filed: March 27, 2017
    Publication date: July 9, 2020
    Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela, Karin Langenberg
  • Patent number: 10696947
    Abstract: The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC).
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: June 30, 2020
    Assignee: NCARDIA B.V.
    Inventor: Stefan Robbert Braam
  • Patent number: 10613078
    Abstract: The current disclosure relates to technology for predicting cardiotoxicity of compounds. In vitro methods using human stem-cell derived cardiomyocytes cultured in specific media are disclosed, as well as kits for use in the method. In the method, the cells are treated with a test compound in combination with a mitochondrial toxicant.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: April 7, 2020
    Assignee: NCARDIA B.V.
    Inventors: Stefan Robbert Braam, Fleur Stevenhagen
  • Publication number: 20180251734
    Abstract: The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.
    Type: Application
    Filed: August 31, 2016
    Publication date: September 6, 2018
    Applicant: Pluriomics B,V,
    Inventors: Stefan Robbert Braam, Ana Catarina Martins Grandela
  • Publication number: 20180038846
    Abstract: The current disclosure relates to technology for predicting cardiotoxicity of compounds. In vitro methods using human stem-cell derived cardiomyocytes cultured in specific media are disclosed, as well as kits for use in the method. In the method, the cells are treated with a test compound in combination with a mitochondrial toxicant.
    Type: Application
    Filed: February 18, 2016
    Publication date: February 8, 2018
    Inventors: Stefan Robbert BRAAM, Fleur STEVENHAGEN
  • Publication number: 20170159018
    Abstract: This disclosure generally concerns the fields of cell biology and molecular biology. In particular the invention concerns the field of stem cell biology and maturation of stem cell-derived cardiomyocytes. Disclosed is a method for improving the maturity of stem-cell derived cardiomyocytes, in particular of the ventricular type, as can be witnessed by, for example, an improved upstroke velocity of the stem-cell derived cardiomyocytes.
    Type: Application
    Filed: June 5, 2015
    Publication date: June 8, 2017
    Inventors: Stefan Robbert Braam, Leon Teroolen, Christine Mummery
  • Publication number: 20160122718
    Abstract: The current disclosure relates to a culture medium, different methods to generate adult-like cardiomyocytes from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC) using the medium, in particular from stem cells that differentiated into (foetal) cardiomyocytes, and to kits comprising the medium, or the medium together with differentiated (foetal) cardiomyocytes derived from pluripotent embryonic stem cells (ESC) and/or (induced) pluripotent stem cells (iPSC).
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Inventor: Stefan Robbert Braam